source from：The pharma letter

Metabolic and digestive disease specialist HighTide Therapeutics has raised S107 million in aseries C financing led by China's TCM Healthcare Fund, with money also from Yuexiu Fundand Yuthai Fund.

The company, which has a footprint in both China and the USA, is working on multifunctionaltherapies, including lead candidate HTD801, a first-in-class candidate for conditionsincluding type 2 diabetes and non-alcoholic steatohepatitis (NASH).

HighTide will use the money to advance clinical development as well as commercializationand business development.

With a Phase II trial in type 2 diabetes near completion, the company has also initiated mid-stage research in NASH and has secured US Fast Track designation for the candidate in NASHas well as primary sclerosing cholangitis (PSC).